- Home
- UFCS vs HUMA Comparison
UFCS vs HUMA Comparison
Compare UFCS & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UFCS | HUMA |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 933.8M | 236.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | UFCS | HUMA |
|---|---|---|
| Price | $37.23 | $1.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $33.00 | $10.13 |
| AVG Volume (30 Days) | 143.7K | ★ 4.2M |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 118.04 | N/A |
| EPS | ★ 4.24 | N/A |
| Revenue | ★ $1,353,781,000.00 | $1,571,000.00 |
| Revenue This Year | $10.11 | N/A |
| Revenue Next Year | $3.33 | $731.05 |
| P/E Ratio | $8.71 | ★ N/A |
| Revenue Growth | ★ 12.12 | N/A |
| 52 Week Low | $24.11 | $1.06 |
| 52 Week High | $37.84 | $6.77 |
Technical Indicators
Market Signals| Indicator | UFCS | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 61.33 | 35.54 |
| Support Level | $36.46 | $1.06 |
| Resistance Level | $37.50 | $1.17 |
| Average True Range (ATR) | 0.94 | 0.08 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 84.57 | 7.11 |
Price Performance
Historical ComparisonAbout UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.